Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
09:00am, Monday, 21'st Apr 2025
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics
10:20am, Friday, 18'th Apr 2025
Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during t
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
08:47am, Friday, 18'th Apr 2025
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
02:10pm, Thursday, 17'th Apr 2025
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Thursday, 17'th Apr 2025
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
02:05pm, Wednesday, 16'th Apr 2025
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
03:53pm, Tuesday, 15'th Apr 2025
Bristol Myers Squibb & Co BMY on Monday announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos (mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructi
Cytokinetics reiterated top pick after Bristol failure at H.C. Wainwright
10:04am, Tuesday, 15'th Apr 2025
H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial evaluating mavacamten in non-obstructive hypertrophic cardi
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
09:20am, Tuesday, 15'th Apr 2025
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
06:15pm, Monday, 14'th Apr 2025
Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.
Bristol Myers' heart disease drug fails to meet main goals in late-stage study
04:24pm, Monday, 14'th Apr 2025
Bristol Myers Squibb said on Monday its experimental drug to treat a type of heart disease did not meet the main goals in a late-stage study.
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
04:15pm, Monday, 14'th Apr 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial.
Trump Says Pharmaceutical Tariffs Coming in Near Future
02:03pm, Monday, 14'th Apr 2025
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with repo
